Preventive effect of vit K, vit D and, risedronate on 3-dimensional trabecular microstructure in patients with IgA nephropathy on glucocorticoid treatment

Preventive effect of vit K, vit D and, risedronate on 3-dimensional trabecular microstructure in patients with IgA nephropathy on glucocorticoid treatment - The Preventive Risedronate Intervention for those Undergoing Steroid therapy with IgA nephropathy (PRIUS-IgA Study )

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002474

Enrollment

Registered

2009-10-01

Start date

2007-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucocorticoid induced osteoporosis in patients with IgA nephropathy

Interventions

Menatetrenone 45mg/day for 6 months Calcitriol 0.5 microgram/day for 6 months Risedronate 17.5mg/week for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inpatients with IgA nephropathy who start glucocorticoid therapy for the first time in the Department of nephrology of Osaka university hospital

Exclusion criteria

Exclusion criteria: 1, women who hope for future pregnancy 2, patients who already have had osteopenia or osteoporosis 3, patients with chronic kidney disease stage 3-5 4, postmenopausal women 5, patients with any prior history of glucocorticoid therapy

Design outcomes

Primary

Measure	Time frame
Changes in 3-dimensional trabecular bone structure at 6-month after the start of intervention	—

Secondary

Measure	Time frame
Changes in bone turnover markers and bone mineral density	—

Countries

Japan

Contacts

Public ContactYoshitaka Isaka

Osaka University Hospital Nephrology

isaka@kid.med.osaka-u.ac.jp06-6879-3857

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026